Highlights

  • Product sales revenue projected at NZD 2.4 million, representing a 41% increase over FY2025.
  • Total revenue expected to reach NZD 2.7 million, up 28% year-on-year.
  • Net loss anticipated at ~NZD 2.2 million, reflecting ongoing investments in market expansion and development.

Truscreen Group Limited (NZX:TRU), a global provider of AI-enabled products, has released updated guidance for the financial year ending 31 March 2026 (FY2026). The Company expects product sales revenue of approximately NZD 2.4 million, an increase of 41% over FY2025, though below market expectations of NZD 2.8 million. Total revenue is forecast at around NZD 2.7 million, up 28% compared with the previous year, while earnings are projected to mirror FY2025 losses at approximately NZD 2.2 million.

Revenue Update and Market Drivers

TruScreen’s revenue outlook has been influenced by delays in key markets. While a signed sales contract has been secured in Uzbekistan, payment is pending before shipment. Additionally, validation delays in Zimbabwe have postponed a second order of 10,000 SUS units into FY2027. Despite these challenges, overall product sales revenue is expected to grow, reflecting ongoing adoption of TruScreen’s AI-enabled technology.

Earnings Guidance and Strategic Investments

The Company anticipates reporting a FY2026 loss similar to FY2025, at around NZD 2.2 million. Contributing factors include increased expenditure to expand market access, alongside a reduction of approximately NZD 200,000 in the Australian Research & Development tax refund due to lower R&D spending. TruScreen continues to invest in its distributor network across Uzbekistan, India, Indonesia, and select African markets to build adoption and market presence that support medium-term profitability.

Clinical Validation Spurs Interest

TruScreen’s AI-enabled technology has gained attention following the publication of a four-year clinical study involving 15,000 patients by the Chinese Obstetricians and Gynaecologists Association (COGA). The study has generated interest in key markets, supporting TruScreen’s strategy to expand its presence and distributor reach internationally.

Financial Metrics (NZD)

  • Product sales revenue (FY2026): 2.4 million (+41%)
  • Total revenue (FY2026): 2.7 million (+28%)
  • Net profit/(loss): ~ (2.2 million)
  • R&D tax refund reduction: ~200,000 lower than FY2025

TruScreen is focused on expanding its global footprint while managing market access delays and investment costs. Despite projected losses for FY2026, the Company’s strategy to enhance product adoption, expand distributor networks, and leverage clinical validation provides a foundation for potential medium-term growth. Continuous updates to the market ensure transparency around key assumptions driving revenue and earnings forecasts.

FAQs

Q1: What is TruScreen’s expected revenue for FY2026?
A1: Product sales revenue is expected to be NZD 2.4 million, with total revenue around NZD 2.7 million, up 28% from FY2025.

Q2: Will TruScreen make a profit in FY2026?
A2: The Company expects to report a net loss of approximately NZD 2.2 million, similar to FY2025, due to market development and investment costs.

Q3: What factors influenced the revenue forecast?
A3: Delays in receiving payments from Uzbekistan and a postponed validation program in Zimbabwe deferred certain sales into FY2027, impacting FY2026 revenue.